Introduction
Biologic agents have been approved for the treatment of rheumatic diseases, plaque psoriasis and inflammatory bowel diseases and have tremendously changed treatment strategies for these debilitating diseases. 1 These agents include abatacept (Orencia ® ), adalimumab (Humira ® ), alefacept (Amevive ® ), anakinra (Kineret ® ), certolizumab pegol (Cimzia ® ), etanercept (Enbrel ® ), golimumab (Simponi ® ), infliximab (Remicade ® ), natalizumab (Tysabri ® ), and rituximab (Rituxan ® ). Evidence suggests that biologics are highly effective, although adverse events such as serious infections, lymphoma, leucopenia, malignancies, or demyelinations are of concern.
2-9 Furthermore, they are considerably more expensive than standard treatment options. 10, 11 The cost of biologic drugs is expected to exceed US$60 billion in 
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the US by 2010, representing a significant portion of the US drug industry. 12 In general, biologic agents work by selectively blocking mechanisms involved in the inflammatory and immune response. For example, the biologics adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab block tumor necrosis factor (TNF). [13] [14] [15] In contrast, abatecept and alefacept interfere with T-lymphocyte activation. 16 Natalizumab binds the alpha(4) integrin, which results in partial blockade of immune-cell adhesion to vascular endothelium and subsequent tissue migration of lymphocytes. 17 Rituximab binds to the CD20 antigen on the surface of B lymphocytes, 18 which are involved in autoimmune anti-inflammatory processes, such as those involved in rheumatoid arthritis (RA). Finally, anakinra is a recombinant IL-1 (interleukin-1) receptor antagonist and has the same properties as the human IL-1 receptor agonist. Anakinra binds to the IL-1 receptor and inhibits pro-inflammatory effects by blocking signal transduction. [4] [5] [6] 19 Dosing regimens and route of administration vary considerably among the various agents. Abatacept, infliximab, and rituximab are administered intravenously; adalimumab, anakinra and etanercept are administered subcutaneously. Abatacept is infused in doses of 500 to 1000 mg repeated at 2 and 4 weeks and every 4 weeks thereafter. Infliximab infusions are administered in doses of 3 mg/kg at 0, 2, and 6 weeks followed by maintenance every 8 weeks and rituximab is dosed at 1000 mg on days 1 and 15. Adalimumab is injected subcutaneously at 40 mg every other week, and etanercept is administered at 50 mg per week. 11 In comparison, anakinra is administered in doses of 100 mg subcutaneously every day. The burden of daily subcutaneous administration of anakinra might disadvantage it compared with the other biologic agents. Table 1 presents a summary of dosing and administration of the biologics.
Considering the high cost and differing regimes of the biologics, it is important to ascertain their comparative effectiveness. This systematic review and meta-analysis is a result of work conducted for the Oregon Drug Effectiveness Review Project (DERP) on the comparative efficacy and safety of 10 specific biologics for rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and juvenile idiopathic arthritis in adult out-patients and subgroups including children. In a meta-analysis of studies up to January 2005 indirect comparisons suggested that anakinra is inferior to the anti-TNF biologics for RA. 20 In this report we focus on the general and comparative benefits and risks of anakinra and provide an update of this result with several newer studies included in the analysis.
Methods

Data sources
We searched MEDLINE ® , Embase, Cochrane Library, and International Pharmaceutical Abstracts from 1980 up to April 2009. We used either Medical Subject Headings (MeSH) as search terms when available or key words when appropriate. In the original DERP report, 11 we combined terms for RA, ankylosing spondylitis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and juvenile idiopathic arthritis with a list of ten specific biologics-abatacept (Orencia ® ), adalimumab (Humira
For this review we limited results to literature identified for anakinra. For the other biologics, we present comparisons with anakinra only. We did not review data on golimumab because it was not on the market at the time of this review, and excluded efalizumamab because it was voluntarily withdrawn from the market. We limited electronic searches to "human" and "English language."
We manually searched reference lists of pertinent review articles and letters to the editor and used the Center for Drug Evaluation and Research database to identify unpublished research submitted to the FFDA. The Scientific Resource Center of the Oregon Health and Science University invited pharmaceutical manufacturers to submit dossiers on completed research for each drug.
Study selection
Two persons independently reviewed abstracts and relevant full-text articles. To assess efficacy or effectiveness for response and quality of life we included randomized controlled trials (RCTs) and prospective controlled observational studies of at least 12 weeks duration that compared anakinra with placebo or another biologic. To assess harms (specific adverse events, rates of adverse events, and discontinuations attributable to adverse events), we also examined data from retrospective observational studies with 100 participants and follow-up of at least 6 months. Table 2 summarizes the eligibility criteria.
If both reviewers agreed that the study did not meet eligibility criteria, we excluded it. We also excluded studies that met eligibility criteria but were reported only Systematic review and meta-analysis of general and comparative effectiveness and safety of anakinra Dovepress submit your manuscript | www.dovepress.com Dovepress as an abstract. Investigators resolved disagreements about inclusion or exclusion by consensus or by involving a third reviewer.
Data extraction and quality assessment
We used a structured data abstraction form into which trained reviewers abstracted data from each study and assigned an initial quality rating. Abstracted data included the baseline characteristics of the included patients, health-related outcomes (such as quality of life, response, remission, pain, hospitalization and mortality), adverse events, and overall and differential attrition. A senior reviewer read each abstracted article, evaluated completeness of data abstraction, and confirmed the quality rating. Investigators resolved any disagreements by discussion and consensus or by consulting an independent party. Infliximab TNF inhibitor iv rA: 3 mg/kg at 0, 2, and 6 weeks followed by maintenance every 8 weeks thereafter; may increase to maximum of 10 mg/kg every 4 weeks AS: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 6 weeks thereafter Plaque psoriasis: 5 mg/kg at 0, 2, and 6 weeks, then every 8 weeks thereafter Ulcerative colitis: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter Pediatric Crohn's disease: 5 mg/kg at 0, 2, and 6 weeks, followed by a maintenance dose of 5 mg/kg every 8 weeks; if no response by week 14, consider discontinuing therapy Natalizumab Alpha 4 integrin blocker iv Crohn's disease: 300 mg infused over 1 hour every 4 weeks rituximab Anti-CD 20a iv rA: 1000 mg on days 1 and 15 in combination with methotrexate Abbreviations: AS, ankylosing spondylitis; CTLA 4-ig, cytotoxic T-lymphocyte antigen 4; TNF, tumor necrosis factor; iL-1, interleukin-1; CD, cluster of differentiation; iM, intramuscular; iv, intravenous; PsA, psoriatic arthritis; rA, rheumatoid arthritis; SQ, subcutaneous.
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We assessed the internal validity (quality) of trials based on predefined criteria and applied ratings of good, fair, or poor. 21 Primary elements of quality assessment for RCTs included randomization and allocation concealment, similarity of compared groups at baseline, blinding, use of intention-to-treat analysis, and overall and differential loss to follow-up. To assess observational studies we used criteria involving selection of cases or cohorts and controls, adjustment for confounders, methods of outcomes assessment, length of follow-up, and statistical analysis. 22 Studies with a fatal flaw in one or more categories were rated "poor" quality.
To identify effectiveness studies, we used a tool that distinguishes efficacy trials from effectiveness studies based on certain elements of study design. 23 Such studies have a higher applicability of results than efficacy trials because they enroll less selected study populations, employ treatment modalities that mimic clinical practice, and assess health outcomes along with adverse events.
Data synthesis
Where data were insufficient to conduct meta-analyses (ie, too sparse or too heterogeneous), we synthesized the evidence on the majority of outcomes qualitatively. Where data from RCTs were sufficient, we conducted meta-analyses. The outcome of interest for efficacy was the number of patients achieving a response according to the ACR scoring system (American College of Rheumatology). We chose ACR50 as the primary outcome measure because a 50% improvement is likely to translate to a clinically significant improvement in health-related quality of life. For example, a patient with 12 swollen and 8 tender joints at baseline would need to have fewer than 6 swollen and 4 tender joints at the trial endpoint. This would be accompanied by at least a 50% improvement in at least 3 of the following 5 measures: the patient's assessment of pain, the patient's assessment of global disease activity, the physician's assessment of global disease activity, the Health Assessment Questionnaire (HAQ)-Disability Index, and either a C-reactive protein (CRP) or sedimentation rate (Westergren erythrocyte sedimentation rate [WESR] ). In addition, we report the results for an ACR20 (20% improvement) and ACR70 (70% improvement).
For each meta-analysis, we conducted a test of heterogeneity (I 2 index) and applied both random and fixed effects models. We consider I 2 greater than 60% to be too high to compare data. We report the random effects results because the results from both models were very similar in all metaanalyses. We assessed publication bias using funnel plots and Kendell's tests. All statistical analyses used StatsDirect Statistical Software program, version 2.6.6 (StatsDirect LTD, 2008).
Because only limited head-to-head evidence on biologics was available, we conducted adjusted indirect comparisons when data was sufficient and trials were of similar design, conducted in similar settings with a comparable patient population. However, because of limited data on individual biologics as active comparators, we assessed the comparative risk of anakinra relative to anti-TNF agents as a class. We based these analyses on the method proposed by Bucher et al. 24 Evidence suggests that adjusted indirect comparisons agree with head-to-head trials if component studies are similar and treatment effects are expected to be consistent in patients included in different trials. 25, 26 Nevertheless, findings must be interpreted cautiously.
Results
In the original DERP report on biologics, we identified 3451 citations from searches and reviews of reference lists. Of these, 236 articles met the inclusion criteria and were included. Some studies had multiple publications. Finally, for this report on anakinra, we included 4 RCTs for efficacy and 5 additional studies for saftey. Figure 1 represents the results of the literature search and the disposition of the literature. We did not find any study that could be classified as an effectiveness trial. All trials reported on anakinra for the treatment of rheumatoid arthritis. We did not locate any publication that met our inclusion criteria for psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, juvenile idiopathic arthritis, Crohn's disease or ulcerative colitis (all other indications covered in the DERP report). 
Articles* included in DERP drug class review (all biologics): n = 236 • 5 on head-to-head non-randomized trial • 1 on an uncontrolled effectiveness study • 147 on placebo controlled trials • 21 on systematic reviews with meta-analyses • 48 on observational studies • 2 on pooled data analysis • 12 on studies deemed to be of poor quality (excluded) Anakinra studies* included in this review: n = 9 • 3 RCTs (anakinra vs placebo) for efficacy • 1 RCT (etanercept alone vs anakinra plus etanercept) for efficacy • 5 studies included for harms *Number of included articles differs from number of included studies due to the fact that some studies have multiple publications.
Titles and abstracts identified through searches: n = 3451
Full-text articles retrieved: 
Efficacy of anakinra
We located 5 publications that met our inclusion criteria for efficacy in patients with rheumatoid arthritis. Three RCTs reported on the efficacy of anakinra compared with placebo, 27-29 and 1 RCT compared anakinra in combination with etanacerpt with etanacerpt alone. 30 We found additional information on ACR response rates for 1 RCT 27 in the CDER database. 31 One RCT was published as an abstract only. 32 Table 3 presents a summary of the included studies.
Population and outcome measures
A total of 1625 patients were included in the trials. All patients suffered from active RA of at least 3 to 6 months duration. Mean disease duration varied between 6 and 10 years. Trials variably allowed concomitant treatment with a stable dose of 
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MTX and/or corticosteroids. Most patients used NSAIDS in addition to the study medication. The majority of patients in the trials had active disease despite therapy with at least one disease-modifying anti-rheumatic drug (DMARD). Patients with an autoimmune disease other than RA, a history of active listeriosis or mycobacterial infection, another infection or recent antibiotic treatment were generally excluded from studies. Between 70% and 80% of trial participants were female. All trials assessed response rates after 24 weeks of therapy as defined by the ACR. One trial also reported the European League Against Rheumatism (EULAR) response rate. 30 In addition, three studies evaluated functional capacity with the HAQ. [27] [28] [29] All studies were funded by Amgen Inc., Thousand Oaks, California.
28-30
Anakinra compared with placebo
Three fair RCTs compared various doses of anakinra with placebo (between 0.04 mg/kg/day and 150 mg/day) for patients with moderate to severe RA that had not responded to DMARDs. [27] [28] [29] Two studies allowed concomitant treatment with MTX. 28, 29 All three studies lasted 24 weeks. In total, 1392 patients were randomized to anakinra (N = 946) or placebo (N = 446). Based on the ACR criteria, significantly more patients receiving anakinra 100 mg/day, 150 mg/day, 1 mg/kg/day, or 2 mg/kg/day responded to treatment compared with placebo. Specifically, the pooled relative risk of an ACR50 response for the approved doses of anakinra compared with placebo is 2.28 (95% CI 1.41 to 3.67). The RR for an ACR20 response is 1.73 (95% CI 1.34 to 2.25) and for an ACR70 response 2.90 (95% CI 1.21 to 6.97) (see Figure 2) . Relative risk (95% confidence interval)
Relative risk (95% confidence interval)
Relative risk (95% confidence interval) 
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In addition, in all three RCTs, patients receiving anakinra demonstrated a greater improvement in health assessment questionnaire (HAQ) than patients receiving placebo score (approximately 0.4 for anakinra compared to 0.2 for placebo; scale values 0 to 3). This result reached statistical significance for all doses except one (2 mg/kg/day).
Comparative efficacy
We did not locate any trials that directly compared anakinra to another biologic. Because of the lack of direct head-to-head evidence for anakinra compared with other biologics we conducted adjusted indirect comparisons based on meta-analyses of placebo-controlled trials to compare the treatment effects of individual biologics. We included data from published studies or from the CDER website. For all analyses we used only data derived from study arms at or near the recommended dosage. We did not perform indirect comparisons for biologics other than adalimumab, etanercept, and infliximab because the populations included in the trials were too heterogenous compared with the anakinra trials and therefore performing indirect comparisons may lead to erroneous conclusions. Appendix 1 summarizes studies included for indirect comparisons.
For ACR50 response, point estimates of anakinra compared with the anti-TNF biologics consistently favored the comparator: adalimumab (RR 0.64, 95% CI 0.36 to 1.14); etanercept (RR 0.41, 95% CI 0.13 to 1.31); and infliximab (RR 0.69, 95%CI 0.41 to 1.18). Compared with anti-TNF agents as a class, the RR of an ACR50 response is 0.67 (95% CI 0.38 to 1.17). That differences do not reach statistical significance is likely attributable to a lack of power. Despite this, the differences may be clinically relevant. Figure 3 depicts results of adjusted indirect comparisons of anakinra with adalimumab, etanercept, infliximab, and anti-TNF drugs as a class. The evidence on abatacept, certolizumab, and rituximab was insufficient or too heterogeneous to be included for indirect comparisons.
General efficacy of anakinra for other indications
We did not locate any published studies of anakinra for psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, juvenile idiopathic arthritis, Crohn's disease, or ulcerative colitis.
Safety of anakinra General safety
For safety we included the three RCTs included for efficacy, 27-29 1 RCT of anakinra plus etanercept compared with etaercerpt alone, 30 and one 6-month RCT of anakinra versus placebo with a 3-year open treatment follow-up phase. [4] [5] [6] 33 In addition, we located 1 RCT that reported the safety results of 3 doses of anakinra. 19 (This study is an extension of Bresnihan et al. Patients who had received placebo in the initial 24 weeks were re-randomized to 30 mg/day, 75 mg/day, or 150 mg/day of anakinra and followed up for an additional 52 weeks). We also included safety data comparing patients taking anakinra and conventional DMARDs from Systematic review and meta-analysis of general and comparative effectiveness and safety of anakinra Dovepress submit your manuscript | www.dovepress.com Dovepress the German RABBIT Registrar (RABBIT = Rheumatoid Arthritis -Observation of Biologic Therapy) 34, 35 and a case series of patients receiving anakinra. 36 Table 4 presents a summary of the studies included for safety.
Overall, between 6.5% and 30% of patients withdrew from anakinra therapy due to adverse events compared with 4% to 13% of patients on placebo. The most common adverse event was injection site reaction. The mean, crude incidence of injection site reactions was 67.2% (95% CI 38.7 to 95.7).
11
Infections occurred in 5% to 33% of patients taking anakinra compared with 12% to 26% of placebo-treated patients. Infections included influenza-like symptoms, respiratory infections, and urinary tract infections. We located 1 systematic review that reported on the safety of anakinra. 37 The authors included all 4 RCTs of anakinra versus placebo for rheumatoid arthritis that we also located.
6,27-29 Thirty serious infections (1.4%) occurred in the anakinra groups compared with 4 in the placebo groups (0.5%). The metaanalysis of the studies demonstrated an odds ratio for serious infections of 2.75 (95% CI 0.91 to 8.35). 37 Two of the 24-week RCTs reported 2 malignancies each that were "not considered to be related to the study medication". 27, 28 The 3-year open label study of anakinra 33 reported a higher than expected incidence of melanoma and lymphoma (incidence compared with data from the general population). The results submitted to the CDER by Amgen reported that "21 malignancies of various types were observed in 2531 rheumatoid arthritis patients treated with anakinra for up to 50 months". We are unable to draw any conclusions regarding malignancy due to the overall small number of participants in the studies.
Comparative harms
We did not locate any studies that directly compared the incidence of adverse events between anakinra and other biologics. We calculated a higher crude incidence of injection site reactions for anakinra (67.2%, 95% CI 38.7 to 95.7) compared with adalimumab (17.5%, 95%CI 7.1 to 27.9) and etanercept (22.4%, 95% CI 8.5 to 36.3). This is consistent with numbers reported in the respective package inserts.
38-40
Combination strategies
Anakinra combined with etanercept compared with etanercept alone
One RCT compared anakinra 100 mg/day combined with 2 different doses of the anti-TNF agent etanercept (25 mg/once a week or 25 mg/twice a week) with etanercept alone (25 mg/twice a week) in 242 patients with moderate rheumatoid arthritis. 30 After 24 weeks of therapy 41% of patients in the etanercept groups had an ACR50 response, compared with 39% of those receiving once weekly etanercept and anakinra, and 31% in the groups who received the combination of twice weekly etanercept and daily anakinra (results not statistically significant). The odds ratio for an ACR50 response for the etanercept plus anakinra groups versus the etanercept alone group was 0.64 (95% CI 0.37 to 1.09).
Furthermore, 15% of patients in the twice-weekly etanercept plus anakinra group experienced a serious adverse event, compared with 2.5% in the etanercept alone group and 5% in the once-weekly etanercept and anakinra group. Twenty-two percent of patients in the anakinra/etanercept once per week group and 20% of the patients randomized to anakinra and etanercept twice per week did not complete the study compared with 7% of patients receiving etanercept alone. Injection-site reactions were the common reason for adverse-event related withdrawal from the study. Injection site reactions occurred in 69% of patients receiving combination therapy compared with 40% of those receiving etanercept alone.
Subgroups
We did not locate any studies that provided results on the efficacy or safety of anakinra for subgroups.
Discussion
In this systematic review, we found 3 RCTs that confirmed the efficacy of anakinra compared with placebo for adult patients with RA. Our results are consistent with several other published systematic reviews of anakinra. 20, [41] [42] [43] In one RCT that used a combination of anakinra and etanercept the response rates were not better than etanercept alone, and the adverse events rates were significantly higher. There appears to be greater harm and no additional benefit in combining anakinra and the anti-TNF drugs.
No direct evidence comparing anakinra and other biologics exists, however our indirect comparision of anakinra and anti-TNF agents as a class revealed a non-significant RR of 0.67 (95% CI 0.38 to 1.17) that favors the anti-TNF drugs adalimumab, etanacerpt and infliximab. The authors of a meta-analysis with indirect comparisons calculated that anakinra is inferior to adalimumab, etanercept and infliximab. 20 This result was statistically significant. Our update, which includes several newer studies of the anti-TNF biologics, indicates a lesser degree of certainty. 
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Patients receiving anakinra experienced more injection site reactions and serious infections than patients receiving placebo. The number of patients in the included trails was too small to reach any conclusions regarding malignancies.
Our review has limitations. We did not locate any direct comparisons of anakinra compared with other biologics. Like other authors, we have relied on indirect comparisons to report the comparative efficacy of anakinra with other biologics. Although evidence suggests that adjusted indirect comparisons agree with head-to-head trials if component studies are similar and treatment effects are expected to be consistent in patients included in different trials, results have to be interpreted cautiously. Many of the underlying assumptions of indirect comparisons are not verifiable and confidence intervals are often wide leading to indeterminate results. Nevertheless, in the absence of direct evidence indirect comparisons can provide valuable information about the comparative efficacy of drugs.
Secondly, publication bias is an issue for all systematic reviews. Selective availability of studies with positive results can seriously bias conclusions of systematic reviews, particularly when the focus is on placebo controlled trials which are generally conducted for regulatory approval by the manufacturer of a specific drug. All three placebo-controlled trials included in this review were funded by Amgen, Thousand Oaks, CA, US, the makers of anakinra.
Finally, all of the studies we included for efficacy were conducted in patients with moderate to severe rheumatoid arthritis with an average disease duration of 6 to 10 years who also took anti-inflammatory drugs, corticosteroids and in 3 trials also methotrexate. The applicability of their results to the average patient with rheumatoid arthritis might be limited.
Conclusion
Anakinra is certainly effective for treating moderate to severe RA that is resistant to traditional DMARDs in comparison with placebo. Indirect comparisons with adalimumab, etanercept and infliximab, however, showed a trend towards greater efficacy for the anti-TNF drugs. Anakinra also seems to be associated with comparably high rates of injection site reactions. The frequency of administration (daily) might also disadvantage anakinra in comparison with these agents, although the subcutaneous route of administration may be preferable to intravenous. Our results and these factors should be taken into account when considering biologic therapy for patients with RA. 
